Noticias de ROIV_US | Rava Bursátil

08/09/2026 ROIV_US — Investing.com

Roivant Sciences stock hits all-time high at 39.99 USD

08/09/2026 ROIV_US — Yahoo Finance

Top Midday Gainers

07/09/2026 ROIV_US — Yahoo Finance

What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)

07/09/2026 ROIV_US — Yahoo Finance

Roivant Wins Approval for the First Oral Dermatomyositis Drug. How Large is the Opportunity?

05/09/2026 ROIV_US — Yahoo Finance

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on…

04/09/2026 ROIV_US — Value Research

Roivant Sciences Ltd. Warrant (ROIVW) Peer Comparison – Compare with Others

04/09/2026 ROIV_US — Value Research

Roivant Sciences Ltd. Warrant (ROIVW) Financials – Balance Sheet, Profit & Loss, Cash Flow

04/09/2026 ROIV_US — careplusvn.com

Roivant Sciences (ROIV) Holds at $34.58 After Modest 0.49% Gain - Leveraged ETF Flow

01/09/2026 ROIV_US — Value Research

Roivant Sciences Ltd. Warrant (ROIVW) Key Financial Ratios – Valuation, Profitability & More

01/09/2026 ROIV_US — Stock Titan

Roivant Sciences (ROIV) president sells 200,000 shares under preset plan

31/08/2026 ROIV_US — Benzinga

FDA Clears First Targeted Dermatomyositis Treatment From Roivant

28/08/2026 ROIV_US — MarketScreener

Roivant Sciences Ltd. Announces FDA Approval And Commercial Launch Of LISRAYA For Dermatomyositis

28/08/2026 ROIV_US — Reuters

US FDA approves Roivant-Priovant's skin and muscle disease drug

28/08/2026 ROIV_US — Yahoo Finance

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately

28/08/2026 ROIV_US — Reuters

Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month

28/08/2026 ROIV_US — TechStock²

Roivant Shares Slide 2.7% Following LISRAYA Approval, Eyes Turn to $2 Billion Revenue Target

24/08/2026 ROIV_US — Stock Titan

Roivant (NASDAQ: ROIV) CFO uses shares to cover RSU taxes

24/08/2026 ROIV_US — DirectorsTalk Interviews

Roivant Sciences Ltd. (ROIV) Stock Analysis: Biotech Innovator with a 15.20% Upside Potential

24/08/2026 ROIV_US — Stock Titan

Roivant (NASDAQ: ROIV) president settles RSU taxes in shares

24/08/2026 ROIV_US — MarketScreener

Roivant Sciences Insider Sold Shares Worth $12,360,813, According to a Recent SEC Filing